Trial Number

138-21

Condition

Leukemia

Participant Age Range

18 years and older

Participant Gender

Any

Enrolling Participants

Yes

Overview

Medical Events of Interest and Health-Related Quality of Life in Chronic Lymphocytic Leukemia Patients Initiating Treatment with Bruton’s Tyrosine Kinase Inhibitors Acalabrutinib or Ibrutinib

Data will be collected from CLL patients in the US who initiated acalabrutinib mono or combination therapy with an anti-CD20 monoclonal antibody (mAb) or ibrutinib mono- or combination therapy with an anti-CD20 mAb within 7 days (before or after) of study enrollment. The study will include both first line of therapy (1LOT) and relapsed/refractory (r/r) CLL patients.

Provider

Related Clinical Trials

Click on the category you are interested in.

Name
Address
Enter Trial number from the area just below the marquee.
How would you prefer to be contacted?
How did you hear about us?
Are you a current MemorialCare patient?
This registration is for:
CAPTCHA This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.